IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025

DOI: 10.17148/IJARCCE.2025.14451

UNVEILING TUMOR EVOLUTION AND DNACOMPOSTION USING SPATIAL DYNAMICS

Harshita.P[1], Thenika.A[2], Umesh Chandra.P[3], Mr.Chitte Anil[4]

Department of CSE(DS), Institute of Aeronautical Engineering, Hyderabad, India[1]

Department of CSE(DS), Institute of Aeronautical Engineering, Hyderabad, India[2]

Department of CSE(DS), Institute of Aeronautical Engineering, Hyderabad, India[3]

Department of CSE(DS), Institute of Aeronautical Engineering, Hyderabad, India[4]

Abstract: A thorough characterization of the evolution process of solid tumors and the composition of circulating tumor DNA would greatly facilitate the development of therapeutic approaches. This work depicts the computational modeling approach towards unearthing the intricate relationship between spatial organization in solid tumors and the circulation tumor DNA. The study assesses how spatial organization makes a difference to the tumor cells' release into the blood flow, the incurred effect on mutational landscapes, and high resolution about the simulation of heterogeneity in circulating tumor DNA. The spatial confinement was found dramatically to affect tumor evolution and ctDNA molecular composition-very important for the design of precision medicine strategies, such as non-invasive biomarker detection and personalized therapeutic interventions. Results suggest that spatial tumor organization affects the timing of ctDNA release, and therefore could influence the sensitivity of liquid biopsy to early tumor tracking and treatment response. Integrate computational models with experimental and clinical data in order to validate predictions, refine understanding of ctDNA dynamics, and push the advance in oncology diagnostics, monitoring, and treatment toward better outcomes in personalized medicine.

Keywords: Evolution of solid tumor, Computational modeling, Comprehensive simulations, Circulating tumour DNA (ctDNA), Non-invasive diagnostics.

I.INTRODUCTION

Cancer is one of the more challenging and complicated diseases, such as that for which the spatiotemporal complexity of dynamic evolution within the spatial context of the tumor microenvironment is characteristic. Unraveling the intricately interwound complex interplay of genetic mutations in tumour cells, spatial distribution of tumor cells, and their microenvironmental influences forms the kernel of understanding tumor evolution and its consequences for treatment effectiveness. The past few years have seen unprecedented advances in computational modeling and in machine learning, empowering a detailed dissection, which now opens the door to spatial dynamics in tumor progression and even to the analysis of composition in circulating DNA fragments.CtDNA in circulation is derived from shedding of tumor cells and allows for non- invasive cancer diagnosis and monitoring. Paper title: "Spatial heterogeneity within a tumor is dominated by the rates of apoptosis and cellular shedding, and impacts the mutational composition of ctDNA that entails genetic bias.This study establishes that regional changes in a microenvironment within the tumor can alter ctDNA patterns substantially due to variations such as type of immune response and hypoxia.Circulating tumor DNA provides a promising approach to the management and treatment of cancers to be diagnosed and monitored non-invasively, from which DNA fragments are shed into the bloodstream from the tumor cells through apoptosis, necrosis, and active secretion.

Variations in the rate of apoptosis are observed among different clones of tumors; the effect is that there will be unequal representation in the circulation DNA, which subsequently impacts the quality of genetic information collected from the blood.

International Journal of Advanced Research in Computer and Communication Engineering
Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025
DOI: 10.17148/IJARCCE.2025.14451

For example, immune infiltration, hypoxia, and treatment regimens also impact the rates of processes considered and therefore tumor evolution and yield of ctDNA. The central question is to understand how the spatial heterogeneity in tumors affects the representation of ctDNA in blood samples and how that impact impacts the accuracy with which cancers are monitored and treated. Important specific issues include:

This study is centered on gaining an insight into the complex relationship that exists between tumor evolution, spatial heterogeneity, and circulating tumor DNA representation. It tries to shed light on how spatial distribution differences create cancer dynamics and lead to shedding of ctDNA. Differential apoptosis rates, heterogeneity in cell shedding and regional biology have all been deemed individually to affect genetic biases in ctDNA samples. This will address dynamics aimed at the enhancement of reliability of diagnostics of cancer treatment, monitoring, and prognostication based on ctDNA. Finally, this research will enhance prediction accuracy on cancer advancement to better tailor the treatments for improved outcomes for the patients.

II. LITERATURE SURVEY

This paper proposes a deep learning method of Gulshan et al. in the automatic detection of diabetic retinopathy with CNNs using a large set of retinal fundus images. The technique maintains as high an accuracy level as that of an expert human being and makes the solution promising enough to be applied as a screening tool for the early detection of diabetic retinopathy. [1]

Ting et al. here describe a deep learning system involving the use of CNNs and image processing techniques for the identification of diabetic retinopathy and associated diseases of the eye. The system showed great sensitivity and specificity and may potentially find useful applications in the clinic for screening eyes for various diseases. [2]

Gargeya and Leng utilized an automated detection technique using CNN analysis for the identification of diabetic retinopathy in retinal images, that classified these images either as normal or containing diabetic retinopathy. The model was accurate to a great extent and efficient in terms of processing. It allowed for large-scale screening initiatives. [3]

Keel et al. designed a computerized diagnostic model with AI that may be used in outpatient endocrinology services for screening diabetic retinopathy. Patient data was bound together by deep learning algorithms to offer personalized recommendations for screening. Thus, it may help decrease the costs of health care by ensuring that patients are not left behind to receive bad care. [4] Eladawi et al. present an automated detection method for diabetic retinopathy through clinical biomarkers and imaging data such as OCT. The system was elaborate on giving insight into vascular anomalies, which offered the clinicians a trace of the progression of the disease to form treatments. [5]

A mobile-based system for the diabetic retinopathy screening using fundus photography and machine learning was made by Rajalakshmi et al. The approach as shown served as a proof of concept for feasibility in resource-limited settings; cost-effective and accessible remote screening solution. [6]

A study was conducted by Abràmoff et al. using an autonomous AI diagnostic system for the detection of diabetic retinopathy in primary care clinics. The high sensitivity and specificity achieved prove the full potential of AI-based screening within real-world health care contexts. [7]

For the detection of diabetic retinopathy, Gangwar and Ravi also employed transfer learning with pre-trained CNNs, which presented higher results than the classical models and confirmed the role of knowledge transfer in the process of medical image analysis. [8]

Araújo et al. considered data augmentation techniques for enhancing deep learning models in an attempt to detect proliferative diabetic retinopathy. The synthetic images enhance robustness and generalization capability of models even when there is limited training data. [9]

Tsiknakis et al. reviewed deep learning models for diabetic retinopathy detection and summarized the current methods and their performances in terms of accuracy, sensitivity, and specificity. It particularly underlines the need for standardized evaluation methods, large-scale validation studies, and actual progress toward applying those models to screening programs. [10]

III. METHODOLOGY

The proposed methodology for tumor growth simulation and ctDNA analysis involves multiple stages, incorporating computational modeling, apoptosis dynamics, treatment simulation, and ctDNA sampling to explore the interplay between tumor spatial heterogeneity and circulating tumor DNA (ctDNA) representation. The tumor growth is modeled using the Eden model, a boundary-driven approach that simulates tumor expansion on a 2D lattice. This model is particularly suitable for capturing spatial heterogeneity, as it focuses on the proliferation of cells along the tumor boundary, reflecting real-life tumor growth patterns.

International Journal of Advanced Research in Computer and Communication Engineering
Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025
DOI: 10.17148/IJARCCE.2025.14451

A Moore neighborhood structure is employed, meaning each tumor cell is surrounded by eight neighboring cells. This structure ensures that growth is determined by local interactions, simulating how cells proliferate in densely packed environments. The simulation begins with a single tumor cell and continues until the tumor reaches a population of 60,000 voxels or becomes extinct due to cellular apoptosis or other dynamics.

3.1 Clinical Detection and Treatment Simulation Apoptosis, or programmed cell death, is integrated into the simulation from the early stages of tumor growth. During the initial phase, a uniform death rate is assumed to represent apoptosis, simulating the natural balance between cell proliferation and death that occurs in early tumor development. As the tumor grows, the detection and treatment phase is triggered when the tumor reaches a 90-voxel radius, simulating the point at which the tumor becomes clinically detectable. At this point, treatment is introduced, and its effects on tumor growth and apoptosis are simulated. The treatment phase models the response of tumor cells to therapeutic interventions by adjusting the rate of cell proliferation and death, enabling the simulation to capture how treatment can slow or reverse tumor growth while increasing apoptosis.

3.2 ctDNA Shedding and Sampling

A critical aspect of the methodology is the assessment of ctDNA, which is shed by tumor cells into the bloodstream and serves as a potential biomarker for cancer detection and monitoring. Throughout the simulation, ctDNA is sampled at different stages of tumor growth, both before and after treatment. This sampling is used to assess how well the ctDNA reflects the genetic composition and spatial heterogeneity of the tumor. By sampling ctDNA at various points in time, the model can capture how the spatial organization of tumor cells influences the amount and type of ctDNA released into circulation. After treatment, additional samples are taken to examine how the intervention affects ctDNA shedding and its genetic makeup. Bias analysis is then conducted to explore how variations in cell shedding due to spatial heterogeneity and apoptosis influence the observed genetic differences in ctDNA.

3.3 High-Dimensional Tumor Evolution Dataset

This methodology highlights the significant impact of spatial tumor heterogeneity on ctDNA release and composition. It allows for the examination of potential biases that may arise in ctDNA sampling, particularly due to uneven cell death and shedding across different tumor regions. These findings are crucial for improving the accuracy of liquid biopsies, as ctDNA is increasingly used as a non-invasive tool for cancer diagnosis and treatment monitoring. By simulating tumor growth, apoptosis, and treatment response, this approach offers a comprehensive understanding of how spatial factors shape ctDNA dynamics and provides insights that could enhance personalized medicine strategies for cancer patients. The tumor evolution analysis of the used dataset is highly challenging due to dimensions, size, and complications due to multiple domains. It comprises multiple attributes that not only offer insight into any corresponding aspect of the growth of the tumor but also include temporal, spatial, genetic, and frequency data. Temporal attributes like "t" and "norm_t" follow the pace of simulation changes with the passage of time. Spatial attributes like "r_mean," "r_std," "centroid_x," "centroid_y," and "centroid_r" present the distribution in space in which the clones of the tumor are moving. Genetic information is collected through attributes like "genotype" and "drivers,"describing rich information over genetic variations and mutations in the tumor. Furthermore, frequency data (e.g., "tissue," "blood," "diff") quantifies the presence of specific genotypes in different environment, and population-related attributes, such as "popsize" and "cellhge," give a clue about the tumor's overall and scaled population sizes. Data manipulation and analyses turn into very sophisticated tasks to enable meaningful insights.In addition, due to multiple replicates at multiple time points and genotypes, the amount of data grows significantly, complicating the analysis even more. Thousands of data points are encapsulated within each replicate, and the high- resolution data generated at each point in time for many clones results in a gigantic dataset which is difficult to store, process, or analyze efficiently. Temporal complexity adds yet another layer of difficulty in the sense that recording changes through time requires the application of sophisticated time-series analysis techniques, even with normalized and binned timestamps such as "norm_t" or "norm_t_binned". Furthermore, spatial attributes introduce spatial complexity, and useful tools such as GeoPandas and Shapely would be required for spatial analysis and distribution visualization of tumor clones. Genetic complexity refers to factors such as the "drivers," mutations, and genetic diversity in tumor clones-features that have to do with the requirement for bioinformatics for handling and data analysis.

IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025

DOI: 10.17148/IJARCCE.2025.14451



Fig 1: Framework for the flow of tumor to analysis.

The image shows comparison graphs of tumor invasion dynamics under different models, with a clear illustration of a difference in clonal fraction between blood and tissue across varying estimated 3D tumor sizes. There are four panels (A, B, C, D):

Panels A and B represent driver-dependent invasion in small (A) and large (B) sanctuary sites. Each shows results for both the quiescent and proliferative cell models. Panels C and D : Driver-independent invasion in similar small (C) and large (D) sanctuary sites for both cell models. Each graph incorporates a color gradient, where normalized age is indicated and therefore ranges from younger clones towards the older clones as blue. The x-axis depicts estimated tumour size, while the y-axis shows the difference in clonal fraction between samples of blood and tissue. Orange lines delineate mean values, highlighting just how different clonal dynamics can be, firstly between quiescent and proliferative cell models and second with or without influence by the sanctuary site.



Fig 2: Discrepancies between Blood and tissue clonal diversity

This figure depicts four graphs that compare clonal diversity between blood and tissue at normalized time under various invasion models and different sanctuary site sizes. In the graphs, the red lines indicate the clonal diversity in **blood, while the lines in blue indicate **tissue**. Shading around lines suggests variability in data.

Panels A and B show driver-dependent invasion for a small(A) and a large(B) sanctuary site. Invasion increases clonal diversity in the blood at a higher rate for large sanctuary sites, whereas tissue diversity remains lower for longer

International Journal of Advanced Research in Computer and Communication Engineering
Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025
DOI: 10.17148/IJARCCE.2025.14451

times.Panels C and D illustrate the idea of driver-independent invasion.large(D) sanctuary sites. In both cases, blood and tissue are sharply increasing late in the normalized time scale of clonal diversity, but more so in the case of the larger sanctuary site.

The graphs above suggest that clonal diversity evolves in blood and tissue differently, in ways sensitive to whether the sanctuary site is small or large, and also to which invasion model obtains.

IV. EXPERIMENTAL EVALUATION

We simulated such complex dynamics of tumor evolution with the help of an Eden model and examined the implications it provides for the analysis of circulating tumor DNA. The Eden model can effectively capture boundary-driven growth in a 2D lattice and is, therefore, well suited to the study of heterogeneity in the spatial growth of tumors. It included two main phases: phase I simulated the development of a tumor from a single cell, and phase II analyzed the representation of ctDNA at different stages of the growth of the tumor and post-treatment. The first phase of the experiment involved the Eden model simulating the development of a tumor with spatial heterogeneity. Starting from a single tumor cell, the model enabled a rapid cell division at the edge of the tumor and slower divisions in the core. This spatial heterogeneity is quite realistic because the growth rate of real tumors typically tends to be faster on the periphery than in the core, because the oxygen levels, nutrient diffusion, or various other environmental conditions will often be more favorable for cell division on the periphery. This 2D lattice mapped a much better difference, thus making the simulation more realistic towards tumor development and progression. The growth of the tumor was allowed to continue until it was rich enough to reach a population of 60,000 voxels, at which point the size was big enough to represent clinically relevant tumor sizes.

In the second phase, apoptosis modeling and ctDNA analysis were included. The differential apoptosis rates were modeled by assuming that after the treatment, the apoptosis rates in the tumor's core and edge regions were dissimilar, respectively, by invoking apoptosis rates for the core and the edges of the tumor corresponding to their respective values: \(d_1\) and \(d_2\). It was an attempt to capture as closely as possible the reality of chemotherapy or immune response not being uniform throughout the tumor and more cell death being at the periphery than at the core of the tumor. This phase set up how changes in the dynamics of the tumour would reflect those in its attendant ctDNA. Interestingly, areas of the tumor that had a higher apoptosis rate contributed disproportionately to ctDNA, potentially making ctDNA a biased subset of the tumor's genetic landscape. Indeed, only mutations in areas with a higher cellular turnover rate - at the edge of the tumor are likely to be found in ctDNA. Changes within the core of tumors, relatively more stable or quiescent, will underestimate in the blood samples. Such spatial heterogeneity in ctDNA greatly hinders its application in clinical diagnostics. Nevertheless, its role as a noninvasive biomarker in the monitoring of the progression of tumors, in minimal residual disease detection, and in identification of actionable mutations for use in targeted therapies is rapidly increasing. The results presented in this study indicate that owing to uneven cell shedding from various regions into the bloodstream, ctDNA may not be a complete reflection of the clonal architecture of the tumor. This means that there is a possibility of misinterpretation of ctDNA- based diagnostics when important driver mutations or alterations in genetics are not represented preferentially in ctDNA. This has serious implications for clinical decision-making, especially in personalized cancer treatment. Understanding the full genetic landscape of a tumor is important to select the appropriate therapies.

To explore this problem more elaborately, the model was sampled at various time points during tumor development and after treatment. The analysis showed profound biases in ctDNA representation depending on spatial heterogeneity of the tumor and differential apoptosis rates applied. ctDNA more frequently reflected mutations within those regions of the tumor where apoptosis was more aggressive, whereas those with lower apoptosis rates were underrepresented. This spatial bias affects both the content of genetic material in ctDNA and the clinical implications of tumor burden and mutation frequency.The authors emphasize further development of more sophisticated models as well as empirical work toward decreasing the accuracy gap and achieving reliability in ctDNA-based diagnostics. A potential route ahead would involve combining computations with experimental data in order to derive more accurate, larger models of ctDNA shedding. Such advancements may also manifest in the form of enhanced algorithms for interpreting ctDNA-derived data or assisting clinicians with spatial heterogeneity when the determinations derive from ctDNA as a treatment guide. Future validation of these computational models should take place using clinical samples to ensure that the models illustrate the complexity of real-world tumors.

Therefore, the Eden model is important for the insight obtained into spatial heterogeneity in growth of tumor and its effects on the composition of ctDNA. It points to the need for accounting for complexity at spatial and genetic levels in tumour evolution when using diagnostics for cancer with a base of ctDNA. Better understanding of the limitations of ctDNA plus models to refine computational analysis can then be used towards further optimization in terms of accuracy of ctDNA analysis to enhance monitoring, decision- making about treatment, and outcome for patients.

IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025

DOI: 10.17148/IJARCCE.2025.14451



Fig 3: Blood clone fraction

The scatter plot is drawn based on tumor size in the x- axis in logarithmic scale and difference between blood clone fraction and tissue clone fraction in the y-axis between -0.2 and 0.4. To depict "norm_age," points are colored with values from 0.0 (yellow), to 0.8 (blue). A number of trend lines corresponding to a range of "norm_age" values are employed. The oscillation of the yellow line (norm_age = 0.0) near zero suggests that clones' proportions do not change strongly with tumour size. In contrast, the blue line (norm_age = 0.8) dips to below zero for large tumours; this might indicate an a depleting or competition interaction between the clones at older tissue ages. Finally, the orange line crosses over and then plateaus; this situation appears to have a unique profile at intermediate ages. This plot suggests that the fraction of clones circulating in blood and tissue increases with increasing tumor size and may be affected by the normalized age of the tissue to some extent, reflecting heterogeneity in clonal dynamics across age groups.



Fig.4: Blood Tissue Growth

The plot of tumor size on a logarithmic scale from to on intratumor heterogeneity (ITH) in blood and tissue samples, as measured by the inverse Simpson's diversity index (y-axis) and representing clonal diversity, is done by the red line for ITH in blood and by the blue line for ITH in tissue. Shaded areas indicate variability or confidence intervals around these measurements. For a small enough tumor (less than \\\\(10^7\\\\)), the values for both blood and tissue ITH are very low and essentially the same. At around a tumor size of \\\\(10^7\\\\) there is a sharp spike in blood ITH which then drops rapidly but increases slowly with tumor growth. The tissue ITH increases much more gradually and steadily and the highest values for tissue ITH occur after tumor size \\\\(10^9\\\\)), although the overall tissue ITH is still less than the blood ITH. What the divergence of blood and tissue ITH levels, particularly for the larger tumors, reflects is a difference in clonal diversity between the two compartments. Blood reflects greater clonal diversity that peaks earlier and fluctuates to a greater degree than does tissue. This may reflect greater or simply more numerous tumor clones in the samples collected in blood when compared with tissue at certain tumor sizes, or fewer of these in tissue samples.

IJARCCE ISSN (O) 2278-1021, ISSN (P) 2319-5940

International Journal of Advanced Research in Computer and Communication Engineering

Impact Factor 8.102 ⁜ Peer-reviewed & Refereed journal ⁜ Vol. 14, Issue 4, April 2025

DOI: 10.17148/IJARCCE.2025.14451

V. CONCLUSION

The developed model for cancer biology represents a significant advancement in understanding the influence of spatial structure on the composition of circulating tumor DNA (ctDNA) and the evolution of solid tumors. It clearly points out that spatial structure plays a crucial role in the modulation of the dynamics of tumor evolution and ctDNA. Spatial tumor evolution refers to changes in a tumor's genomic content as the tumor grows and spreads throughout the body; ctDNA are the breakdown products that are released from the tumor cells into the bloodstream, allowing one to non- invasively determine the genetic make up of the tumor. The vast majority of earlier efforts have been directed at characterizing the direction of genomic composition change along different regions of the tumor and how such changes effect treatment response and disease progression.

Yet, our model shows higher performance than prior approaches in incorporating both spatial structure and dynamic ctDNA into a single framework to further explain tumor heterogeneity. Since cell-free DNA can be analyzed, targetable mutations or biomarkers can be found for more-personalized treatment regimes-an approach that is not only non-invasive but also superior to traditional biopsies. This model impacts the clinic in very many ways in terms of improvement in diagnosing cancer, treatment, and evaluation of prognosis. The insights obtained from this modeling approach may help clinicians understand the trajectory of tumor evolution and therefore provide more effective and targeted treatments. This model can also help identify ctDNA biomarkers that could improve the accuracy of treatment plans and the probability of succeeding for patients. This system has proven to be a key tool in advancing research on cancer. The application of the system on multiple datasets and its demonstration show that it can robustly and reliably work with real-world scenarios of cancer evolution and ctDNA composition. Its modular architecture makes it relatively easy for different tumor growth analysis, spatial structure mapping, and ctDNA prediction flows toward better model adaptability and scalability for broader clinical applications. The performance of the model in improved parameters, such as prediction of tumor evolution and dynamics of ctDNA, is better than its previous versions with regard to predictability and applicability in real-world settings. Modular architecture indeed ensures application of this model in different clinical settings to pave the way for new approaches in the field of precision oncology. It serves to be highly relevant to develop new and innovative cancer treatment strategies through the advanced understanding of tumor biology, which is a big step forward for enhancing the patient outcome.

VI. FUTURE SCOPE

Promising pathways toward near future directions include the further development and refinement of our understanding of the impact of spatial structure on tumor evolution and dynamics of circulating DNA (ctDNA). The advancements in computational modeling techniques, which include the more sophisticated simulations of tumor growth and heterogeneity, will allow a deeper investigation into how spatial influence contributes to the progression of the tumor and resistance to treatment. The combination of multimodal data sources, such as imaging techniques and single-cell sequencing, with the analysis process might eventually make ctDNA analysis much more precise and thus more suitable for real-time monitoring of tumor evolution. The real-world applications will be in the following extensive clinical trials and validation studies testing the accuracy of ctDNA-based diagnostics and prognostics in different types of cancers and diverse patient populations. Additionally, these studies might help in further validation of guided use of ctDNA for decision-making in treatment steps as part of personalized medicine programs. Iterative testing will further refine models and data interpretation in such a way that the predictions for the detection of tumor mutations and responses to therapy will be made more accurate. Another promising frontier is adaptive AI- driven models that could learn from patient-specific data streams, continuously refining predictions of patterns of tumor evolution and ctDNA shedding. The adaptability will boost precision oncology with tailor- made insights based on dynamic, real-time changes in a patient's tumor biology. Ensuring that the technologies are used ethically in ways that respect ethical standards for data use and patient privacy will be important in building trust and achieving wider adoption.

In a nutshell, this project promises new standards in precision oncology due to strong advancements in the area of diagnostics and treatments for cancer. Through future development, the strategies of improving early detection, personalization of treatments, and monitoring might lead to more effective interventions while improving patient outcomes to pave the way for innovative approaches in the care of cancer.

VII. ACKNOWLEDGEMEMNT

We seize this opportunity to thank each individual who supported, motivated, and cooperated with us in this project at every level. I take great pleasure in acknowledging the help provided by the key persons who ensured that our project culminated successfully. We thank **Mr. Chitte Anil**, assistant professor of data science and my supervisor.

DOI: 10.17148/IJARCCE.2025.14451

Deep regards are extended to the faculty of the Data Science department for all that they do while developing this project. No success would have been achieved without their advice, cooperation, and encouragement. We would like to thank our friends, in special, for their help in the development of this project. Last but not the least, we wish to present our thanks to our principal, Dr. L V Narasimha Prasad, the management, and my parents, for their constant support in all walks of life.

REFERENCES

[1]. Abouali H, Hosseini SA, Purcell E, Nagrath S, Poudineh M. Recent advances in device engineering and computational analysis for characterization of cell- released cancer biomarkers. *Cancers (Basel)*. 2022;14(2):288.

[2]. Avanzini S, Kurtz DM, Chabon JJ, Moding EJ, Hori SS, Gambhir SS, et al. A mathematical model of ctDNA shedding predicts tumor detection size. *Sci Adv*. 2020;6(50):eabc4308. doi:10.1126/sciadv.abc4308

[3]. Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, et al. The spatiotemporal evolution of lymph node spread in early breast cancer. *Clin Cancer Res*. 2018;24(19):4763–70.

[4]. Bozic I, Paterson C, Waclaw B. On measuring selection in cancer from subclonal mutation frequencies. *PLoS Comput Biol*. 2019;15(9):e1007368.

[5]. Bredno J, Lipson J, Venn O, Gross S, Fields AP, Beausang JF, et al. Tumor area and microscopic extent of invasion to determine circulating tumor DNA fraction in plasma and detectability of colorectal cancer (CRC). *J Clin Oncol*.2020;38(4_suppl):243. doi:10.1200/JCO.2020.38.4_suppl.243

[6]. Buckland ST, Magurran AE, Green RE, Fewster RM. Monitoring change in biodiversity through composite indices. *Philos Trans R Soc Lond B Biol Sci*. 2005;360(1454):243–54.

[7]. Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, et al. Clonal replacement during neoadjuvant treatment of breast cancer involves heterogeneity for HER2 and other oncogenes within reinstantiating clones. *Nat Commun*. 2019;10(1):657. doi:10.1038/s41467-019- 08593-4

[8]. Cha Y, Kim S, Han S. Using plasma circulating tumor DNA sequencing for precision medicine in the management of solid cancers.*Cancer ResTreat.* 2023;55(2):367–84.

[9]. Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. *Mol Cancer Ther*. 2017;16(7):1412–20.

[10]. Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, et al. Circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer: Clinical implications. *Oncologist*. 2019;24(6):820–8.